Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study
Publication in refereed journal


Times Cited
Altmetrics Information
.

Other information
AbstractAim: To investigate whether the benefit of combining aflibercept with 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) chemotherapy could be confirmed in patients from the Asia-Pacific region (ClinicalTrials.gov: NCT01661270). Patients & methods: Asian patients with oxaliplatin-pretreated metastatic colorectal cancer were randomized to receive aflibercept or placebo, followed by FOLFIRI. The primary end point was progression-free survival. Results: The intention-to-treat population comprised 332 patients. A clinical supply misallocation resulted in 198/332 (60%) patients receiving at least one cycle of misallocated treatment. Nevertheless, the addition of aflibercept to FOLFIRI was shown to improve progression-free survival (hazard ratio: 0.629; 95% CI: 0.488–0.812). Adverse events were in line with expectations. Conclusion: The beneficial treatment effect associated with the addition of aflibercept to FOLFIRI was confirmed in Asian patients with pretreated metastatic colorectal cancer.

Lay Abstract
The Phase III VELOUR study showed that the addition of aflibercept to FOLFIRI chemotherapy significantly improved outcome in a predominantly western population of patients with metastatic colorectal cancer (mCRC), who had failed prior oxaliplatin-containing therapy. This Phase III study confirmed the aflibercept treatment effect and benefit in patients from the Asia-Pacific region with oxaliplatin-pretreated mCRC.
Acceptance Date27/03/2018
All Author(s) ListLi J, Xu RH, Qin SK, Liu TS, Pan HM, Xu JM, Bi F, Lim R, Zhang SZ, Ba Y, Bai YX, Fan NF, Tsuji A, Yeh KH, Ma B, Wei V, Shi DM, Magherini E, Shen L, Shen L
Journal nameFuture Oncology
Detailed descriptionEpub 2018 Aug 17
Year2018
Month8
Volume Number14
Issue Number20
PublisherFuture Medicine
Pages2031 - 2044
ISSN1479-6694
LanguagesEnglish-United Kingdom
Keywordsaflibercept, Asia-Pacific, FOLFIRI, mCRC, oxaliplatin-pretreated
Web of Science Subject CategoriesOncology;Oncology

Last updated on 2020-16-09 at 03:40